DE05014998T1 - Schweinecircoviren, Nukleinsäuren, Polypeptide und Impfstoffe - Google Patents

Schweinecircoviren, Nukleinsäuren, Polypeptide und Impfstoffe Download PDF

Info

Publication number
DE05014998T1
DE05014998T1 DE05014998T DE05014998T DE05014998T1 DE 05014998 T1 DE05014998 T1 DE 05014998T1 DE 05014998 T DE05014998 T DE 05014998T DE 05014998 T DE05014998 T DE 05014998T DE 05014998 T1 DE05014998 T1 DE 05014998T1
Authority
DE
Germany
Prior art keywords
nucleic acid
acid fragment
sequence
expression vector
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
DE05014998T
Other languages
English (en)
Inventor
Gordon Allan
Brian Meehan
Edward Clark
John Ellis
Deborah Haines
Lori Hassard
John Harding
Catherine Elisabeth Charreyre
Gilles Emile Chappuis
Francis Mcneilly
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Saskatchewan
Boehringer Ingelheim Animal Health France SAS
Queens University of Belfast
Original Assignee
University of Saskatchewan
Merial SAS
Queens University of Belfast
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27253376&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE05014998(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from FR9712382A external-priority patent/FR2769321B1/fr
Priority claimed from FR9800873A external-priority patent/FR2769322B1/fr
Priority claimed from FR9803707A external-priority patent/FR2776294B1/fr
Application filed by University of Saskatchewan, Merial SAS, Queens University of Belfast filed Critical University of Saskatchewan
Publication of DE05014998T1 publication Critical patent/DE05014998T1/de
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
    • A23C19/00—Cheese; Cheese preparations; Making thereof
    • A23C19/02—Making cheese curd
    • A23C19/032—Making cheese curd characterised by the use of specific microorganisms, or enzymes of microbial origin
    • A23C19/0321—Propionic acid bacteria
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
    • A23C19/00—Cheese; Cheese preparations; Making thereof
    • A23C19/02—Making cheese curd
    • A23C19/032—Making cheese curd characterised by the use of specific microorganisms, or enzymes of microbial origin
    • A23C19/0323—Making cheese curd characterised by the use of specific microorganisms, or enzymes of microbial origin using only lactic acid bacteria, e.g. Pediococcus and Leuconostoc species; Bifidobacteria; Microbial starters in general
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16741—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16743—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/10011—Circoviridae
    • C12N2750/10021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/10011—Circoviridae
    • C12N2750/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/10011—Circoviridae
    • C12N2750/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/10011—Circoviridae
    • C12N2750/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2750/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/10011—Circoviridae
    • C12N2750/10061—Methods of inactivation or attenuation
    • C12N2750/10064—Methods of inactivation or attenuation by serial passage

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Nukleinsäurefragment, dadurch gekennzeichnet, daß es eine Sequenz des Genoms eines porcinen Circovirus (PCV) Typ II gemäß SEQ ID NO: 1 enthält.

Claims (23)

  1. Nukleinsäurefragment, dadurch gekennzeichnet, daß es eine Sequenz des Genoms eines porcinen Circovirus (PCV) Typ II gemäß SEQ ID NO: 1 enthält.
  2. Nukleinsäurefragment, dadurch gekennzeichnet, daß es eine Sequenz des Genoms eines PCV Typ II mit mindestens 76% Homologie zu der Sequenz nach Anspruch 1 enthält.
  3. Nukleinsäurefragment, dadurch gekennzeichnet, daß die Sequenz des PCV Typ II-Genoms fähig ist, spezifisch mit der Sequenz nach Anspruch 1 zu hybridisieren.
  4. Nukleinsäurefragment nach Anspruch 3, dadurch gekennzeichnet, daß die Hybridisierung unter Bedingungen mit hoher Stringenz durchgeführt wird.
  5. Nukleinsäurefragment, dadurch gekennzeichnet, daß es eine Sequenz des Genoms eines porcinen Circovirus (PCV) Typ II ausgewählt aus der Reihe SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4 und SEQ ID NO: 6 enthält.
  6. Nukleinsäurefragment, dadurch gekennzeichnet, daß es eine Sequenz, die fähig ist, spezifisch mit einer der Sequenzen nach Anspruch 5 zu hybridisieren.
  7. Nukleinsäurefragment nach Anspruch 6, dadurch gekennzeichnet, daß die Hybridisierung unter Bedingungen mit hoher Stringenz durchgeführt wird.
  8. Nukleinsäurefragment, dadurch gekennzeichnet, daß es die Sequenz nach einem der Ansprüche 1 bis 7 ganz oder teilweise enthält, wobei das genannte Fragment eine Sequenz enthält, die für ein Epitop codiert, welches fähig ist, beim Schwein eine Immumreaktion gegen PCV Typ II zu induzieren.
  9. Nukleinsäurefragment nach Anspruch 8, dadurch gekennzeichnet, daß das Epitop mindestens 13 bis 25 Aminosäuren enthält.
  10. Nukleinsäurefragment, dadurch gekennzeichnet, daß es die Sequenz nach einem der Ansprüche 1 bis 7 ganz oder teilweise enthält, wobei dieses Fragment für ein Polypeptid codiert, das mindestens ein offenes Leseraster (OLR) enthält.
  11. Nukleinsäurefragment nach Anspruch 10, dadurch gekennzeichnet, daß das OLR aus der Gruppe OLR 1 bis 13, vorzugsweise OLR 4, 7, 10 und 13, stammt.
  12. Polypeptid, das von dem Nukleinsäurefragment nach einem der Ansprüche 1 bis 11 codiert wird.
  13. Expressionsvektor, der ein Nukleinsäurefragment nach einem der Ansprüche 1 bis 11 enthält und der ein Polypeptid in vitro exprimiert.
  14. Expressionsvektor nach Anspruch 13, dadurch gekennzeichnet, daß es sich um ein Baculovirus handelt.
  15. Expressionsvektor nach einem der Ansprüche 13 bis 14, dadurch gekennzeichnet, daß er ein Polypeptid in E. coli oder Insektenzellen oder Eukaryontenzellen, vorzugsweise aus der Gruppe der Hefen oder Säugetierzellen, exprimiert.
  16. Polypeptide, die von einem Expressionsvektor nach einem der Ansprüche 13 bis 15 produziert wurden.
  17. Spaltimpfstoff, der mindestens ein Polypeptid nach Anspruch 12 oder 16 in einem tierärztlich annehmbaren Träger- oder Verdünnungsmittel sowie gegebenenfalls einen tierärztlich annehmbaren Hilfsstoff enthält.
  18. Expressionsvektor, dadurch gekennzeichnet, daß er ein Nukleinsäurefragment nach einem der Ansprüche 1 bis 11 in sein Genom in vivo integriert und ein Polypeptid exprimiert.
  19. Expressionsvektor nach Anspruch 18, dadurch gekennzeichnet, daß er ausgewählt ist aus der Gruppe der lebenden Viren, die entweder natürlich nicht pathogen sind oder für das Schwein attenuiert worden sind, und den Plasmiden.
  20. Expressionsvektor nach Anspruch 19, dadurch gekennzeichnet, daß er zur Vermehrung im Schwein fähig ist.
  21. Expressionsvektor nach einem der Ansprüche 18 bis 20, dadurch gekennzeichnet, daß das Virus ausgewählt ist aus der Gruppe Schweine-Herpesviren wie Virus der Aujeszky-Krankheit, Schweine-Adenovirus, Poxviren, insbesondere Vaccinia-Virus, Avipox-Virus, Canarypox-Virus, Schweinepocken-Virus.
  22. Lebend- oder Plasmidimpfstoff, dadurch gekennzeichnet, daß er mindestens einen Expressionsvektor nach einem der Ansprüche 18 bis 21 enthält.
  23. Impfstoff nach Anspruch 22, dadurch gekennzeichnet, daß er weiterhin ein tierärztlich annehmbares Träger- oder Verdünnungsmittel enthält.
DE05014998T 1997-10-03 1998-10-01 Schweinecircoviren, Nukleinsäuren, Polypeptide und Impfstoffe Pending DE05014998T1 (de)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
FR9712382A FR2769321B1 (fr) 1997-10-03 1997-10-03 Nouveaux circovirus porcins, vaccins et reactifs de diagnostics
FR9712382 1997-10-03
FR9800873 1998-01-22
FR9800873A FR2769322B1 (fr) 1997-10-03 1998-01-22 Nouveaux circovirus porcins, vaccins et reactifs de diagnostic
FR9803707A FR2776294B1 (fr) 1998-03-20 1998-03-20 Nouveaux circovirus porcins ; vaccins et reactifs de diagnostic
FR9803707 1998-03-20

Publications (1)

Publication Number Publication Date
DE05014998T1 true DE05014998T1 (de) 2008-11-20

Family

ID=27253376

Family Applications (7)

Application Number Title Priority Date Filing Date
DE200512000009 Pending DE122005000009I1 (de) 1997-10-03 1998-10-01 Schweinecircoviren abgeleitete Impfstoffe.
DE69830858A Expired - Lifetime DE69830858D1 (de) 1997-10-03 1998-10-01 Schweinecircoviren
DE69816460T Expired - Lifetime DE69816460T2 (de) 1997-10-03 1998-10-01 Schweinecircoviren abgeleitete impfstoffe
DE122008000069C Pending DE122008000069I1 (de) 1997-10-03 1998-10-01 Schweinecircoviren abgeleitete impfstoffe
DE05014998T Pending DE05014998T1 (de) 1997-10-03 1998-10-01 Schweinecircoviren, Nukleinsäuren, Polypeptide und Impfstoffe
DE69839227T Expired - Lifetime DE69839227T2 (de) 1997-10-03 1998-10-01 Verfahren zur in vitro-Diagnose von Infektionen durch Schweinecircovirus vom Typ II und diagnostische Reagenzien
DE69830858T Expired - Lifetime DE69830858T4 (de) 1997-10-03 1998-10-01 Schweinecircoviren

Family Applications Before (4)

Application Number Title Priority Date Filing Date
DE200512000009 Pending DE122005000009I1 (de) 1997-10-03 1998-10-01 Schweinecircoviren abgeleitete Impfstoffe.
DE69830858A Expired - Lifetime DE69830858D1 (de) 1997-10-03 1998-10-01 Schweinecircoviren
DE69816460T Expired - Lifetime DE69816460T2 (de) 1997-10-03 1998-10-01 Schweinecircoviren abgeleitete impfstoffe
DE122008000069C Pending DE122008000069I1 (de) 1997-10-03 1998-10-01 Schweinecircoviren abgeleitete impfstoffe

Family Applications After (2)

Application Number Title Priority Date Filing Date
DE69839227T Expired - Lifetime DE69839227T2 (de) 1997-10-03 1998-10-01 Verfahren zur in vitro-Diagnose von Infektionen durch Schweinecircovirus vom Typ II und diagnostische Reagenzien
DE69830858T Expired - Lifetime DE69830858T4 (de) 1997-10-03 1998-10-01 Schweinecircoviren

Country Status (21)

Country Link
US (1) US6368601B1 (de)
EP (4) EP1281760B9 (de)
JP (5) JP5008218B2 (de)
KR (4) KR100854615B1 (de)
CN (2) CN100584948C (de)
AT (3) ATE245191T1 (de)
AU (1) AU756554C (de)
BR (1) BR9812845B1 (de)
CA (1) CA2305623C (de)
CY (3) CY1110359T1 (de)
DE (7) DE122005000009I1 (de)
DK (4) DK1281760T5 (de)
ES (4) ES2524359T3 (de)
FR (1) FR05C0021I2 (de)
HK (1) HK1095161A1 (de)
HU (2) HU230340B1 (de)
NL (1) NL300326I2 (de)
PL (1) PL198506B1 (de)
PT (4) PT1386617E (de)
UA (1) UA78180C2 (de)
WO (1) WO1999018214A1 (de)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060029617A1 (en) * 1997-10-03 2006-02-09 Charreyre Catherine E Porcine circovirus and Helicobacter combination vaccines and methods of use
US6391314B1 (en) * 1997-10-03 2002-05-21 Merial Porcine circoviruses vaccines diagnostic reagents
US7192594B2 (en) * 1997-10-03 2007-03-20 Merial Limited Postweaning multisystemic wasting syndrome and porcine circovirus from pigs
US7211379B2 (en) * 1997-10-03 2007-05-01 Merial Sas Prevention of myocarditis, abortion and intrauterine infection associated with porcine circovirus-2
US6517843B1 (en) 1999-08-31 2003-02-11 Merial Reduction of porcine circovirus-2 viral load with inactivated PCV-2
FR2781159B1 (fr) * 1998-07-06 2000-10-06 Merial Sas Vaccin circovirus et parvovirus porcin
FR2772047B1 (fr) * 1997-12-05 2004-04-09 Ct Nat D Etudes Veterinaires E Sequence genomique et polypeptides de circovirus associe a la maladie de l'amaigrissement du porcelet (map), applications au diagnostic et a la prevention et/ou au traitement de l'infection
US20040062775A1 (en) * 1997-12-05 2004-04-01 Agence Francaise De Securite Sanitaire Des Aliments Circovirus sequences associated with piglet weight loss disease (PWD)
PT2363488E (pt) * 1997-12-11 2015-01-13 Univ Belfast Síndrome multi-sistémica do definhamento pós-desmame de porcos
EP1816200B1 (de) * 1997-12-11 2016-03-09 Merial Virus des multisystemischen Kümmersyndroms bei Absatzferkeln
US6497883B1 (en) * 1999-06-10 2002-12-24 Merial Porcine circovirus recombinant poxvirus vaccine
US6943152B1 (en) * 1999-06-10 2005-09-13 Merial DNA vaccine-PCV
ES2170622B1 (es) * 1999-12-03 2004-05-16 Consejo Superior De Investigaciones Cientificas Clones y vectores infectivos derivados de coronavirus y sus aplicaciones.
WO2001096377A2 (en) * 2000-06-15 2001-12-20 Purdue Research Foundation Vaccine for congenital tremors in pigs
US7018638B2 (en) * 2000-12-19 2006-03-28 Wyeth Mycoplasma hyopneumoniae bacterin vaccine
EP1379671B1 (de) * 2001-03-27 2009-05-06 University of Saskatchewan Verfahren zur kultivierung von circovirus
CA2454397A1 (en) 2001-07-20 2003-06-05 The University Of Georgia Research Foundation, Inc. Attenuated rabies virus with nucleoprotein mutation at the phosphorylation site for vaccination against rabies and gene therapy in the cns
US7279166B2 (en) 2001-12-12 2007-10-09 Virginia Tech Intellectual Properties, Inc. Chimeric infectious DNA clones, chimeric porcine circoviruses and uses thereof
US7276353B2 (en) 2001-12-12 2007-10-02 Virginia Tech Intellectual Properties, Inc. Chimeric infectious DNA clones, chimeric porcine circoviruses and uses thereof
EA011578B1 (ru) * 2002-08-26 2009-04-28 Пфайзер Продактс Инк. Иммуногенная композиция для защиты крупного рогатого скота от инфекций респираторной и репродуктивной систем и ее применение
KR20040021988A (ko) * 2002-09-06 2004-03-11 서상희 바이러스 증식용 돼지 신장 상피 세포주, 및 이의 용도
UA95602C2 (ru) 2004-12-30 2011-08-25 Берингер Ингельхейм Ветмедика, Инк. Иммуногенная композиция цвс2 и способы приготовления такой композиции
US7833707B2 (en) * 2004-12-30 2010-11-16 Boehringer Ingelheim Vetmedica, Inc. Methods of overexpression and recovery of porcine circovirus type 2 ORF2
US7700285B1 (en) 2005-12-29 2010-04-20 Boehringer Ingelheim Vetmedica, Inc. PCV2 immunogenic compositions and methods of producing such compositions
US8834891B2 (en) 2005-03-14 2014-09-16 Boehringer Ingelheim Vetmedica, Inc. Immunogenic compositions comprising Lawsonia intracellularis
JP5408998B2 (ja) * 2005-04-13 2014-02-05 メリアル リミテッド ブタサーコウイルス産生アッセイ
EP1792996A1 (de) * 2005-12-01 2007-06-06 Consejo Superior de Investigaciones Cientificas Nukleinsäuren, kodierend für Impfstoffe gegen den reproduktiven und respiratorischen Syndrom Virus (prrsv)
WO2007094893A2 (en) 2005-12-29 2007-08-23 Boehringer Ingelheim Vetmedica, Inc. Use of a pcv2 immunogenic composition for lessening clinical symptoms in pigs
RU2488407C2 (ru) 2005-12-29 2013-07-27 Берингер Ингельхайм Ветмедика, Инк. Поливалентные иммуногенные композиции pcv2 и способы получения таких композиций
KR100870077B1 (ko) * 2006-10-27 2008-11-25 권영득 이유후 전신소모성증후군(ｐｍｗｓ)의 치료용 복합제조성물
US20100129397A1 (en) * 2006-12-11 2010-05-27 Boehringer Ingelheim Vetmedica, Inc. Effective method of treatment of porcine circovirus and lawsonia intracellularis infections
PL2094872T5 (pl) 2006-12-15 2020-10-05 Boehringer Ingelheim Animal Health USA Inc. Leczenie świń seropozytywnych wobec przeciwciała anty-pcv2 antygenem pcv2
EP1941903A1 (de) 2007-01-03 2008-07-09 Boehringer Ingelheim Vetmedica Gmbh Prophylaxe und Behandlung von PRDC
EP1958644A1 (de) * 2007-02-13 2008-08-20 Boehringer Ingelheim Vetmedica Gmbh Vorbeugung und Behandlung von subklinischer PCVD
CN101688185B (zh) * 2007-05-11 2013-05-22 淡马锡生命科学研究院有限公司 对2型猪环状构象病毒(pcv2)感染高度容许的均质细胞系的产生
KR100948127B1 (ko) * 2007-06-27 2010-03-18 주식회사 중앙백신연구소 복합호흡기 질환 돼지의 조직유제를 함유하는 백신 조성물
US20090017064A1 (en) * 2007-07-10 2009-01-15 Wyeth Methods and Compositions for Immunizing Pigs Against Porcine Circovirus
US7829274B2 (en) * 2007-09-04 2010-11-09 Boehringer Ingelheim Vetmedica, Inc. Reduction of concomitant infections in pigs by the use of PCV2 antigen
RU2493254C9 (ru) * 2007-12-21 2013-12-20 ВАЙЕТ ЭлЭлСи Способы и композиции для иммунизации свиней против свиного цирковируса
AU2008347235A1 (en) * 2007-12-31 2009-07-16 Boehringer Ingelheim Vetmedica, Inc. PCV2 ORF2 virus like particle with foreign amino acid insertion
CA2712006A1 (en) 2008-01-23 2009-10-15 Boehringer Ingelheim Vetmedica, Inc. Pcv2 mycoplasma hyopneumoniae immunogenic compositions and methods of producing such compositions
TWI627281B (zh) 2009-09-02 2018-06-21 百靈佳殷格翰家畜藥品公司 降低ｐｃｖ－２組合物殺病毒活性之方法及具有改良免疫原性之ｐｃｖ－２組合物
TWI442935B (zh) 2010-12-22 2014-07-01 Sbc Virbac Ltd 豬第二型環狀病毒（Ｐｏｒｃｉｎｅ Ｃｉｒｃｏｖｉｒｕｓ Ｔｙｐｅ ２）、含彼之免疫組合物、檢測套組及其應用
EP2564869A1 (de) 2011-09-02 2013-03-06 Ceva Sante Animale Synthetische Kapsidproteine und deren Verwendungen
EP2789346A1 (de) 2013-04-11 2014-10-15 CEVA Santé Animale SA Fusionspolypeptide und Impfstoffe
WO2014182872A1 (en) 2013-05-08 2014-11-13 Protatek International, Inc. Vaccine for pcv2 and mycoplasma
US9987348B2 (en) 2013-09-25 2018-06-05 Zoetis Services Llc PCV2B divergent vaccine composition and methods of use
CN105658660A (zh) 2013-10-02 2016-06-08 勃林格殷格翰动物保健公司 Pcv2 orf2蛋白变体和由其组成的病毒样颗粒
CN104383527A (zh) * 2014-11-18 2015-03-04 天津瑞普生物技术股份有限公司 一种猪圆环病毒2型灭活冻干疫苗的制备方法
EP3034609A1 (de) 2014-12-19 2016-06-22 Ceva Sante Animale Rekombinanter Schweinepockenvirus und Impfstoffe
US9944904B2 (en) 2015-05-14 2018-04-17 Merial Inc. Method for porcine circovirus production and PCV2 vaccines
EP3254692A1 (de) 2016-06-10 2017-12-13 Ceva Sante Animale Multivalente rekombinante spv
EP3720485A1 (de) 2017-12-08 2020-10-14 Ceva Sante Animale Rekombinanter schweinepockenvirus und impfstoffe
CA3091982A1 (en) 2018-03-26 2019-10-03 Boehringer Ingelheim Animal Health USA Inc. Method of producing an immunogenic composition
MX2020013484A (es) 2018-06-11 2021-05-27 Ceva Sante Animale Vacunacion contra circovirus porcinos.
KR102124260B1 (ko) * 2018-10-19 2020-06-26 대한민국(관리부서 질병관리본부장) 신속 면역크로마토그래피법을 이용한 콜레라균 진단·탐지 키트 및 이를 위한 특이항체와 항체생산세포주
US20230241198A1 (en) 2020-07-24 2023-08-03 Boehringer Ingelheim Animal Health USA Inc. Combination porcine vaccine

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4745051A (en) 1983-05-27 1988-05-17 The Texas A&M University System Method for producing a recombinant baculovirus expression vector
US4740468A (en) 1985-02-14 1988-04-26 Syntex (U.S.A.) Inc. Concentrating immunochemical test device and method
US5030558A (en) 1986-11-07 1991-07-09 Syntex (U.S.A.) Inc. Qualitative immunochromatographic method and device
US5232835A (en) 1986-11-07 1993-08-03 Syntex (U.S.A.) Inc. Qualitative immunochromatographic method and device
CA1303983C (en) 1987-03-27 1992-06-23 Robert W. Rosenstein Solid phase assay
EP0291194B8 (de) 1987-04-27 2003-10-22 Inverness Medical Switzerland GmbH Immunoassays und Vorrichtungen dafür
US4855240A (en) 1987-05-13 1989-08-08 Becton Dickinson And Company Solid phase assay employing capillary flow
US5120643A (en) 1987-07-13 1992-06-09 Abbott Laboratories Process for immunochromatography with colloidal particles
DE3852918T2 (de) * 1987-09-28 1995-07-13 Beecham Inc TGEV-Virus vom Schwein als Impfstoff für Hunde.
ATE240401T1 (de) 1989-03-21 2003-05-15 Vical Inc Expression von exogenen polynukleotidsequenzen in wirbeltieren
FR2649013B1 (fr) 1989-07-03 1991-10-25 Seppic Sa Vaccins et vecteurs de principes actifs fluides contenant une huile metabolisable
US5141850A (en) 1990-02-07 1992-08-25 Hygeia Sciences, Inc. Porous strip form assay device method
WO1991018627A1 (en) 1990-05-29 1991-12-12 Smithkline Beecham Corporation Swine pneumonia vaccine and method for the preparation thereof
US5238652A (en) 1990-06-20 1993-08-24 Drug Screening Systems, Inc. Analytical test devices for competition assay for drugs of non-protein antigens using immunochromatographic techniques
US5565205A (en) 1990-08-16 1996-10-15 Solvay Animal Health, Inc. Inactivated Mycoplasma hypopneumoniae bacterin and method of use thereof
US5266497A (en) 1990-08-31 1993-11-30 Japan Synthetic Rubber Co., Ltd. Immunochromatographic assay with improved colored latex
US5451504A (en) 1991-07-29 1995-09-19 Serex, Inc. Method and device for detecting the presence of analyte in a sample
ATE131067T1 (de) 1991-10-14 1995-12-15 Akzo Nobel Nv Impfstoff gegen das fortpflanzungs- und atmungssyndrom bei schweinen (prrs) und diagnose.
US5338543A (en) * 1992-02-27 1994-08-16 Ambico, Inc. Thimerosal inactivated mycoplasma hyopneumoniae vaccine
DE9204303U1 (de) 1992-03-30 1992-06-25 Marx, Günter Wolfgang, 7953 Bad Schussenried Trainingsgerät
EP0571648A1 (de) 1992-05-26 1993-12-01 Chung-Nan Weng Gegen mycoplasmale Lungenentzündung schützender Impfstoff
US6592873B1 (en) * 1992-10-30 2003-07-15 Iowa State University Research Foundation, Inc. Polynucleic acids isolated from a porcine reproductive and respiratory syndrome virus (PRRSV) and proteins encoded by the polynucleic acids
FR2700957B1 (fr) 1993-01-29 1995-03-03 Seppic Sa Composition de vaccin sous-unitaire recombinant vivant et procédé de préparation.
KR100374295B1 (ko) 1993-02-08 2003-12-24 바이엘 코포레이션 돼지생식및호흡증후군바이러스의생육방법과백신에서그의용도
FR2702373B1 (fr) 1993-03-08 1996-06-07 Rhone Merieux Emulsions vaccinales fluides eau-dans-l'huile contenant une huile métabolisable.
EP0620277A1 (de) 1993-03-18 1994-10-19 Merck & Co. Inc. Nukleinsäure als pharmazeutische Zubereitungen
ES2074950B1 (es) 1993-09-17 1996-03-16 Iberica Cyanamid Vacuna para la prevencion de la enfermedad reproductiva y respiratoria de la cerda.
CA2181832C (en) 1994-01-27 2012-11-27 Harriet L. Robinson Immunization by inoculation of dna transcription unit
PT676467E (pt) * 1994-04-11 2002-02-28 Akzo Nobel Nv Estirpes europeias de vacina do virus do sindroma reprodutivo e respiratorio porcino (prrsv)
WO1996004091A1 (en) * 1994-08-05 1996-02-15 Schneider Karl P Self-chamfering drill bit
FR2781159B1 (fr) * 1998-07-06 2000-10-06 Merial Sas Vaccin circovirus et parvovirus porcin
FR2772047B1 (fr) * 1997-12-05 2004-04-09 Ct Nat D Etudes Veterinaires E Sequence genomique et polypeptides de circovirus associe a la maladie de l'amaigrissement du porcelet (map), applications au diagnostic et a la prevention et/ou au traitement de l'infection
PT2363488E (pt) * 1997-12-11 2015-01-13 Univ Belfast Síndrome multi-sistémica do definhamento pós-desmame de porcos
KR100298125B1 (ko) * 1999-04-15 2001-09-13 정명식 구리의 화학 증착에 유용한 유기 구리 전구체

Also Published As

Publication number Publication date
ATE299531T1 (de) 2005-07-15
EP1386617A1 (de) 2004-02-04
KR100736129B1 (ko) 2007-07-06
CN101724606A (zh) 2010-06-09
JP5362750B2 (ja) 2013-12-11
NL300326I2 (nl) 2008-04-01
CN100584948C (zh) 2010-01-27
EP1741785A1 (de) 2007-01-10
CN101724606B (zh) 2016-02-24
EP1019510B1 (de) 2003-07-16
JP2011135875A (ja) 2011-07-14
AU756554B2 (en) 2003-01-16
PL339631A1 (en) 2001-01-02
PT1741785E (pt) 2014-11-13
JP2008086317A (ja) 2008-04-17
KR20090051274A (ko) 2009-05-21
FR05C0021I2 (de) 2005-10-21
ATE245191T1 (de) 2003-08-15
EP1386617B1 (de) 2008-03-05
HK1095161A1 (en) 2007-04-27
PT1386617E (pt) 2008-06-17
JP5869658B2 (ja) 2016-02-24
KR100904852B1 (ko) 2009-06-25
DK1281760T3 (da) 2005-10-31
PT1281760E (pt) 2005-11-30
EP1281760B9 (de) 2005-12-28
DK1386617T3 (da) 2008-07-07
KR20010030930A (ko) 2001-04-16
EP1281760B1 (de) 2005-07-13
KR20080023271A (ko) 2008-03-12
AU756554C (en) 2003-09-18
CY1108113T1 (el) 2014-02-12
PL198506B1 (pl) 2008-06-30
DK1741785T3 (da) 2014-11-10
DK1281760T5 (da) 2006-04-18
DK1019510T3 (da) 2003-11-10
EP1019510A1 (de) 2000-07-19
DE69816460T2 (de) 2004-05-27
CA2305623A1 (fr) 1999-04-15
KR20060079256A (ko) 2006-07-05
DE69830858T2 (de) 2006-04-20
ES2246001T3 (es) 2006-02-01
US6368601B1 (en) 2002-04-09
CN1278301A (zh) 2000-12-27
NL300326I1 (nl) 2008-03-03
PT1019510E (pt) 2003-11-28
ES2203984T3 (es) 2004-04-16
DE69816460D1 (de) 2003-08-21
JP2001519159A (ja) 2001-10-23
CA2305623C (en) 2008-04-01
UA78180C2 (uk) 2007-03-15
JP2012193179A (ja) 2012-10-11
WO1999018214A1 (fr) 1999-04-15
HU230340B1 (hu) 2016-02-29
FR05C0021I1 (de) 2005-05-27
BR9812845A (pt) 2000-08-08
DE122008000069I1 (de) 2009-11-05
KR100944144B1 (ko) 2010-02-24
JP4680245B2 (ja) 2011-05-11
DE69839227T2 (de) 2009-03-12
BR9812845B1 (pt) 2010-03-09
EP1281760A1 (de) 2003-02-05
HU226247B1 (en) 2008-07-28
AU9355598A (en) 1999-04-27
HUP0003756A3 (en) 2003-03-28
KR100854615B1 (ko) 2008-08-27
ES2302885T3 (es) 2008-08-01
EP1741785B1 (de) 2014-10-01
CY1115749T1 (el) 2017-01-25
CY1110359T1 (el) 2015-04-29
DE122005000009I1 (de) 2005-08-04
DE69830858D1 (de) 2005-08-18
ATE387914T1 (de) 2008-03-15
DE69839227D1 (de) 2008-04-17
ES2524359T3 (es) 2014-12-05
JP5008218B2 (ja) 2012-08-22
HUP0003756A2 (hu) 2001-02-28
JP2015109840A (ja) 2015-06-18
DE69830858T4 (de) 2006-12-21
HU0800330D0 (en) 2008-07-28

Similar Documents

Publication Publication Date Title
DE05014998T1 (de) Schweinecircoviren, Nukleinsäuren, Polypeptide und Impfstoffe
O'Tousa et al. The Drosophila ninaE gene encodes an opsin
Allen et al. Characterization of an equine herpesvirus type 1 gene encoding a glycoprotein (gp13) with homology to herpes simplex virus glycoprotein C
DK179290A (da) Rekombinante cmv-neutraliserende proteiner
CA2283462A1 (en) Vectors having enhanced expression and methods of making and uses thereof
DK200601181A (da) Fiskevaccine
EP0414689A4 (en) Pox virus vectors
DE20251T1 (de) Dns-transfer-vektor, damit transformierter wirt, impfstoff und ihre herstellung.
DE3650650T2 (de) Vakzin gegen Varicella Zoster Virus
KR900700508A (ko) 인간의 호흡기 합포체성 바이러스에 대한 당단백질 면역 단편을 함유하는 키메라(chimeric) 당단백질
ATE420190T1 (de) Rekombinanter lebendimpfstoff, der katzenherpesvirus typ i enthält, insbesondere für die behandlung von infektiöser bauchfellentzündung bei katzen
DE977852T1 (de) Damilie von immunregulatoren mit der bezeichnung leukozyten immunglobulin-ähnliche rezeptoren (lir)
NZ598605A (en) Vaccine against african horse sickness virus
Clarke et al. Regions of an Eimeria tenella antigen contain sequences which are conserved in circumsporozoite proteins from Plasmodium spp. and which are related to the thrombospondin gene family
Ge et al. Cloning and sequencing of goldfish activin subunit genes: strong structural conservation during vertebrate evolution
CA2182888A1 (en) Nucleotide and amino acid sequences of canine herpesvirus gb, gc and gd and uses therefor
Liu et al. Identification, Molecular Cloning, and Transcription Analysis of theChoristoneura fumiferanaNuclear Polyhedrosis VirusSpindle-like ProteinGene
Hall et al. Identification of an Amsacta spheroidin-like protein within the occlusion bodies of Choristoneura entomopoxviruses
US5871738A (en) Nematode vaccine
Wada et al. MSG gene cluster encoding major cell surface glycoproteins of rat Pneumocystis carinii
CA2459769C (en) Igf-1 as feline vaccine adjuvant, in particular against feline retroviruses
DE69534945T2 (de) Impfstoff für die infektiöse peritonitis der katzen
Thoelen et al. Characterization of a cDNA encoding the bovine coxsackie and adenovirus receptor
Brewer et al. Comparison of the amino acid sequences of tissue-specific parvalbumins from chicken muscle and thymus and possible evolutionary significance
DE69814884T2 (de) Hepatitis b virale polypeptide